Freyr GRI

Every regulatory professional knows the feeling.

You start your day with a list of priorities, only to find new guidance documents, regulatory updates, safety communications, and compliance changes demanding immediate attention. Before long, most of the day is spent reviewing information, tracking updates, and responding to evolving requirements.

Now multiply that challenge across dozens of global markets.

This is the reality facing regulatory affairs teams today.

The life sciences industry has entered an era where information is growing faster than organizations can manually process it. Regulatory complexity continues to increase, submission requirements are becoming more demanding, and health authorities expect companies to remain continuously compliant.

The question many organizations are asking is simple:

How can regulatory teams keep up without constantly increasing resources?

Increasingly, the answer involves artificial intelligence.

The New Reality of Regulatory Affairs

Regulatory affairs has always been a critical business function. Whether supporting pharmaceuticals, biotechnology products, medical devices, or consumer healthcare products, regulatory teams play a central role in bringing products to market and maintaining compliance throughout the product lifecycle.

However, the scope of regulatory responsibilities has expanded significantly.

Today's teams must:

Monitor regulatory changes globally

Manage increasingly complex submissions

Support post-market surveillance activities

Coordinate cross-functional compliance efforts

Track evolving agency expectations

Ensure ongoing regulatory readiness

The challenge isn't expertise.

The challenge is scale.

There is simply too much information for teams to process manually with the speed and consistency modern business environments require.

Why Traditional Regulatory Processes Are Being Reconsidered

For many years, organizations relied on manual workflows to manage regulatory activities.

Teams monitored agency websites, reviewed guidance updates, maintained spreadsheets, exchanged emails, and coordinated activities through traditional document-based processes.

While these methods remain important, they often struggle under the weight of today's regulatory complexity.

As global operations expand, organizations need systems that can continuously monitor information, identify relevant updates, and support faster decision-making.

This growing need has accelerated interest in regulatory affairs automation and AI-powered regulatory intelligence.

How AI Is Supporting Regulatory Teams

Artificial intelligence is particularly effective in environments where large volumes of information need to be reviewed, categorized, and analyzed.

This makes regulatory affairs a natural fit.

AI technologies can help organizations:

Process large regulatory datasets

Identify relevant regulatory changes

Classify and organize documents

Improve information retrieval

Support submission readiness activities

Enhance compliance monitoring

Rather than replacing regulatory professionals, AI helps remove repetitive tasks that consume valuable time and resources.

This enables teams to focus on activities that require expertise, judgment, and strategic thinking.

Regulatory Intelligence Is Becoming a Strategic Advantage

One area where AI is creating significant value is regulatory intelligence.

Every year, regulatory authorities publish thousands of updates that may impact products, markets, and compliance strategies.

Monitoring this information manually is both time-consuming and resource-intensive.

AI-driven regulatory intelligence platforms help organizations automatically collect, analyze, and prioritize regulatory developments based on relevance.

Instead of searching through countless updates, teams receive focused intelligence that supports faster business decisions.

This shift allows organizations to move from reactive compliance management toward proactive regulatory planning.

In today's competitive environment, that capability can provide a meaningful advantage.

AI for Regulatory Submissions: Improving Efficiency

Submission preparation remains one of the most labor-intensive activities within regulatory affairs.

From document compilation and content management to formatting and quality review, preparing submissions requires extensive coordination across multiple stakeholders.

Artificial intelligence is helping streamline these processes.

Modern solutions can support:

Document classification

Metadata generation

Content organization

Completeness checks

Information retrieval

Workflow automation

Generative AI is also beginning to support content development activities by assisting with draft creation and knowledge extraction.

While final review and approval remain firmly under human control, these technologies can significantly reduce administrative workloads.

As submission volumes continue to grow, these efficiencies become increasingly valuable.

Pharmacovigilance and Safety Monitoring Are Also Evolving

Another area benefiting from AI adoption is pharmacovigilance.

Safety teams manage large volumes of adverse event information originating from multiple channels and jurisdictions.

Detecting important safety signals quickly is critical for both patient safety and regulatory compliance.

AI technologies can help analyze incoming information, identify patterns, and highlight potential concerns for expert review.

This allows safety professionals to focus their attention where it matters most while maintaining high standards of oversight and quality.

The combination of technology and human expertise can strengthen both efficiency and consistency across safety operations.

Why Human Expertise Still Matters Most

Despite the growing capabilities of AI, regulatory affairs remains a people-driven profession.

Technology can organize information, automate workflows, and accelerate analysis.

What it cannot do is replace regulatory judgment.

Experienced professionals understand how to interpret agency expectations, evaluate risks, develop regulatory strategies, and make decisions that influence product success.

These responsibilities require context, experience, and critical thinking.

The organizations seeing the greatest value from AI are not those attempting to replace experts.

They are the organizations empowering experts with better tools.

A Smarter Approach to Regulatory Transformation

Successful AI adoption starts with identifying high-volume, repetitive activities that create operational bottlenecks.

Many organizations begin with:

Regulatory intelligence monitoring

Regulatory surveillance

Submission document management

Compliance tracking

Workflow automation

These areas often provide measurable benefits while minimizing implementation risks.

Over time, organizations can expand their capabilities as teams gain confidence and experience with AI-enabled processes.

The Road Ahead

Artificial intelligence is no longer a future concept in regulatory affairs.

It is becoming an increasingly practical solution for organizations seeking to manage complexity, improve efficiency, and strengthen compliance programs.

As regulatory requirements continue to evolve, the ability to transform information into actionable intelligence will become even more important.

For life sciences organizations exploring this transformation, platforms like Freya Intelligence are demonstrating how AI-powered regulatory intelligence can support smarter regulatory decision-making and continuous compliance monitoring.

The future of regulatory affairs will not be defined by automation alone.

It will be defined by how effectively organizations combine human expertise, regulatory knowledge, and intelligent technologies to navigate an increasingly complex regulatory landscape.

AI in Regulatory Affairs: What’s Changing and What Isn’t

Most regulatory teams have stopped asking whether AI matters.

The real question now is: which use cases deliver measurable value?

We explored where AI is genuinely changing regulatory affairs, from regulatory intelligence to pharmacovigilance and beyond.

Front-of-Pack Labeling (FOPL): A Growing Compliance Consideration for Dietary Supplements

Front-of-Pack Labeling (FOPL) is no longer a peripheral consideration in nutrition policy. It has become an increasingly important regulatory mechanism for communicating nutrient risks and, in some jurisdictions, influencing whether products can enter or remain in the market.

For dietary supplement manufacturers, this shift is particularly significant. While traditional dosage forms may remain outside the scope of certain FOPL systems, hybrid and food-like formats are increasingly being captured. Gummies, effervescent tablets, ready-to-mix powders, fortified beverages, and other non-traditional supplement formats may meet the legal definition of a food or beverage depending on jurisdiction-specific classification criteria. As a result, they may become subject to the same front-of-pack labeling requirements that apply to conventional packaged foods.

This creates a structural compliance challenge. Manufacturers must assess not only ingredient composition, but also product format, intended use, and local regulatory classifications. Assumptions based on historical product categorization are no longer sufficient.

Key Global FOPL Frameworks

Although FOPL requirements vary across regions, most systems can be grouped into five broad regulatory models. Understanding these frameworks is essential for developing a harmonized global labeling strategy.

Expansion of Scope

FOPL requirements are increasingly extending to functional foods, fortified products, and non-traditional supplement formats. Early product classification assessments across target markets are becoming essential.

Digital Integration

Regulatory requirements increasingly extend beyond physical packaging. For example, Singapore's Nutri-Grade requirements apply not only to product packaging but also to online advertisements, e-commerce listings, and vending machine displays.

Advertising Impact

Labeling outcomes may influence marketing permissions. In some jurisdictions, products that receive lower ratings or trigger warning labels may be subject to advertising restrictions, placement limitations, or constraints on child-directed marketing.

Nutrient Threshold Sensitivity

Threshold-based systems drive enforcement. Sugar, sodium, and saturated fat levels should be evaluated against local regulatory thresholds early in product development to minimize labeling triggers.

Execution and Monitoring

Prescriptive design and presentation requirements continue to evolve. Accurate implementation and ongoing regulatory monitoring are necessary to maintain compliance over time.

Enabling Global Readiness

As FOPL frameworks continue to expand, supplement manufacturers should adopt a proactive compliance strategy. Aligning product portfolios with nutrient-profiling requirements, conducting early-stage classification assessments, and incorporating FOPL impact evaluations into product development workflows are increasingly becoming baseline compliance expectations.

FOPL should not be viewed solely as a regulatory obligation. It is also emerging as a visible indicator of transparency and product credibility—attributes that consumers increasingly value when making purchasing decisions. Organizations that integrate FOPL considerations early in product design can reduce compliance risks, improve market readiness, and strengthen their competitive position across global markets.

Some regulatory workflows sound like ten browser tabs playing audio at the same time 😅

And teams still need clear direction on what matters next.

That’s why more organizations are moving toward continuous regulatory intelligence where signals are monitored, interpreted, and structured into decision-ready insight in real time.

A little more harmony for teams working in constant motion.

See how freya.intelligence helps teams stay aligned across complex regulatory landscapes.

Good regulatory decisions need the right formula 🧪

Global signals, local requirements, source data, and language complexity all need to come together before teams can move forward with confidence.

That’s where freya.intelligence supports the process continuously monitoring signals, structuring context, and helping teams work with expert-validated regulatory intelligence in real time.

The result is a clearer view of what changed, why it matters, and what deserves attention next. Ready to work with continuous regulatory intelligence?

In the world of Life Sciences, "waiting and seeing" is a high-risk strategy.

Regulations evolve, pivot, and occasionally move the goalposts mid-game. If your compliance strategy is still reactive, you aren't just behind the curve; you’re arguably not even on the track.

The secret to market entry acceleration is about having a "translator" for the global regulatory landscape.

From the FDA's risk-benefit focus to the PMDA’s documentation rigor, we’re breaking down how Regulatory Intelligence transforms compliance into a competitive edge.

The life sciences industry is undergoing rapid transformation as regulatory authorities around the world continue to strengthen compliance expectations. Pharmaceutical companies, biotechnology firms, medical device manufacturers, and cosmetics organizations are now required to manage increasingly complex regulatory frameworks while simultaneously accelerating innovation and global expansion.

With regulatory guidelines constantly evolving, businesses face growing pressure to remain compliant across multiple jurisdictions. A single missed update, delayed submission, or compliance oversight can lead to approval delays, product recalls, financial losses, and reputational damage.

To address these challenges, organizations are increasingly relying on regulatory intelligence consulting to improve compliance operations, reduce regulatory risk, and support faster market access. Regulatory intelligence consulting has become a critical component of modern compliance management because it helps businesses transform regulatory information into strategic business insights.

As global regulations continue to change, companies that invest in proactive regulatory intelligence are better positioned to achieve sustainable growth and maintain competitive advantage in international markets.

What Is Regulatory Intelligence Consulting?

Regulatory intelligence consulting refers to the process of collecting, monitoring, analyzing, and applying regulatory information from global health authorities and industry bodies. The purpose of regulatory intelligence is to help organizations understand changing compliance requirements and make informed regulatory decisions.

Regulatory intelligence consultants provide guidance on evolving regulations related to:

Pharmaceuticals

Medical devices

Biotechnology products

Cosmetics

Food supplements

Combination products

Clinical research

Pharmacovigilance

Product labeling

Quality systems

These consultants monitor updates from regulatory agencies worldwide and provide businesses with actionable insights that support compliance planning and submission strategy.

In highly regulated industries, staying informed about changing regulations is essential for maintaining uninterrupted market access and operational efficiency.

Why Regulatory Complexity Is Increasing

Global healthcare regulations are becoming more detailed and interconnected. Regulatory authorities are continuously updating compliance standards to address emerging technologies, patient safety concerns, data privacy requirements, and digital healthcare innovations.

Organizations operating internationally must now navigate a wide range of regulatory systems, including those governed by:

FDA in the United States

EMA in Europe

PMDA in Japan

MHRA in the United Kingdom

NMPA in China

CDSCO in India

TGA in Australia

MFDS in South Korea

Each agency has unique regulatory procedures, submission requirements, technical standards, and review processes.

For example, one market may prioritize clinical trial evidence, while another may emphasize documentation structure, localization, or post-market safety monitoring. These differences create major operational challenges for companies managing global product portfolios.

Regulatory intelligence consulting helps businesses understand these jurisdiction-specific requirements and align their compliance strategies accordingly.

The Importance of Proactive Compliance Management

Traditional compliance models often rely on reactive processes where organizations respond to regulatory changes only after they become mandatory. However, reactive compliance management increases operational risk and reduces organizational agility.

Modern regulatory environments require proactive compliance strategies that focus on continuous monitoring and early risk identification.

Regulatory intelligence consultants help organizations:

Anticipate regulatory changes

Track emerging guidance updates

Monitor enforcement trends

Identify potential compliance gaps

Improve audit preparedness

Support strategic planning

Reduce submission risks

By identifying upcoming regulatory changes early, businesses can make informed operational adjustments before compliance issues arise.

This proactive approach minimizes disruptions and supports long-term regulatory stability.

How Regulatory Intelligence Supports Market Entry

Expanding into international markets requires more than product innovation. Companies must also understand local regulatory expectations and submission pathways.

Regulatory intelligence consulting plays a major role in accelerating global market access by helping organizations prepare effective submission strategies for different regions.

Consultants support market entry activities by providing insights into:

Product classification requirements

Registration pathways

Local clinical evidence expectations

Labeling regulations

Technical documentation standards

Translation requirements

Submission timelines

Regulatory review trends

Without proper regulatory intelligence, organizations may experience avoidable approval delays, additional information requests, or rejected submissions.

Accurate regulatory planning improves submission quality and reduces the likelihood of costly compliance setbacks.

The Role of AI and Automation in Regulatory Intelligence

Technology is rapidly transforming the regulatory affairs industry. Regulatory intelligence consulting now increasingly incorporates artificial intelligence, automation, and digital monitoring systems to improve efficiency and data accuracy.

Traditional manual monitoring methods are no longer sufficient due to the massive volume of regulatory information being published globally.

AI-powered regulatory intelligence solutions can automatically:

Monitor health authority websites

Detect regulatory updates

Analyze compliance trends

Generate automated alerts

Centralize regulatory information

Support predictive analytics

Improve reporting efficiency

Automation significantly reduces the manual workload associated with compliance tracking while improving response times and decision-making quality.

Organizations that leverage AI-driven regulatory intelligence gain faster access to critical information and improve their ability to adapt to changing regulations.

Data Management and Regulatory Compliance

Effective data management has become a cornerstone of successful compliance operations. Regulatory data is often distributed across multiple departments, systems, and geographic regions, making it difficult to maintain consistency and visibility.

Poor data management can create several compliance challenges, including:

Inconsistent documentation

Delayed submissions

Reduced traceability

Audit risks

Duplicate processes

Incomplete records

Regulatory intelligence consulting helps organizations establish centralized data management frameworks that improve compliance efficiency and operational transparency.

Modern regulatory operations increasingly rely on:

Centralized regulatory databases

Master data management systems

Standardized workflows

Digital document repositories

Automated reporting tools

These systems improve collaboration, enhance data accuracy, and support faster regulatory decision-making.

Benefits of Regulatory Intelligence Consulting

Organizations that invest in regulatory intelligence consulting gain several strategic advantages.

Faster Regulatory Approvals

Better submission planning reduces review delays and improves approval timelines.

Reduced Compliance Risk

Continuous monitoring helps organizations identify and address compliance issues early.

Improved Operational Efficiency

Automation and centralized intelligence reduce manual work and improve workflow management.

Better Global Expansion Support

Regulatory consultants help organizations navigate complex international requirements more effectively.

Enhanced Strategic Decision-Making

Actionable insights support informed business and regulatory planning.

Stronger Regulatory Readiness

Organizations remain prepared for changing global compliance expectations.

Choosing the Right Regulatory Intelligence Partner

Selecting the right regulatory intelligence consulting provider is critical for long-term compliance success.

An effective consulting partner should offer:

Global Regulatory Expertise

Comprehensive understanding of international regulations and submission frameworks.

Local Market Knowledge

Country-specific expertise for regional compliance requirements.

Technology Capabilities

AI-driven monitoring tools and automation platforms that improve intelligence delivery.

Strategic Support

Customized recommendations aligned with business goals and product strategies.

End-to-End Compliance Services

Support across product development, registration, and post-market activities.

Industry Experience

Proven expertise in pharmaceuticals, medical devices, biotechnology, and healthcare sectors.

The right partner helps organizations build scalable compliance frameworks capable of adapting to future regulatory challenges.

Why Regulatory Intelligence Is a Competitive Advantage

Regulatory intelligence is increasingly viewed as a strategic business asset rather than a back-office compliance function.

Organizations with advanced regulatory intelligence capabilities can respond faster to regulatory changes, accelerate product launches, and improve overall operational resilience.

In highly competitive industries, the ability to anticipate regulatory shifts and act quickly creates significant market advantages.

Strong regulatory intelligence also helps organizations:

Improve stakeholder confidence

Build stronger relationships with regulators

Enhance brand reputation

Support innovation

Reduce operational uncertainty

As healthcare regulations continue to evolve, businesses that prioritize regulatory intelligence will be better prepared to compete globally.

The Future of Regulatory Intelligence Consulting

The future of regulatory compliance will depend heavily on digital transformation, predictive analytics, and real-time intelligence systems.

Regulatory agencies themselves are increasingly adopting digital review platforms and data-centric compliance models. As a result, companies must modernize their internal regulatory operations to keep pace.

Future regulatory intelligence strategies will focus on:

AI-driven analytics

Automated compliance monitoring

Predictive risk assessment

Integrated intelligence platforms

Real-time reporting

Global regulatory harmonization

Advanced data governance

Organizations that embrace these technologies early will improve compliance agility and long-term operational performance.

Conclusion

Regulatory intelligence consulting has become an essential part of modern compliance management for life sciences organizations. As global regulations continue to evolve, businesses need proactive intelligence, advanced technology, and expert guidance to navigate increasingly complex compliance environments.

From improving market entry strategies to reducing regulatory risks and accelerating approvals, regulatory intelligence consulting delivers measurable value across every stage of the product lifecycle.

The FDA Reviewed PFAS in Cosmetics. Here's What Every Manufacturer Needs to Understand.

There is a version of the PFAS conversation that most manufacturers are already familiar with: contamination, trace levels, supply chain exposure. That conversation, while important, is not the one regulators are most focused on right now.

The conversation that matters more — and carries greater compliance weight — is about PFAS that brands put into their products on purpose.

Intentional Use Is the Regulatory Flashpoint

"Intentionally added PFAS" has become a precise regulatory term, and the precision is intentional. It refers to per- and polyfluoroalkyl substances selected by a manufacturer as functional ingredients — chosen for the water and oil resistance they provide, the durability they impart, or the texture improvement they deliver.

These are not accidents of the supply chain. They are formulation decisions. And because they are decisions, regulators hold manufacturers directly accountable for them.

The scale of that accountability is significant. The FDA's review found 51 PFAS intentionally added as ingredients across 1,744 cosmetic and personal care formulations on the U.S. market. The practice is widespread, the ingredients are varied, and the regulatory expectations attached to them are growing.

What the FDA's Safety Assessment Actually Shows

The FDA evaluated the 25 most commonly used PFAS ingredients in cosmetics and categorized them by safety profile. The results are worth understanding in detail — because where your ingredients land on this spectrum has direct implications for how you manage them going forward.

Lower Safety Concern: PTFE, Perfluorodecalin, HC Yellow No. 13, Perfluorohexane, and Tetrafluoropropene currently sit in the most favorable position, assessed as presenting relatively lower risk under typical use conditions. This offers a degree of formulation stability — for now.

Potential Safety Concern: Perfluorohexylethyl Triethoxysilane is the ingredient that demands immediate formulation attention. At higher concentrations in leave-on products, particularly body lotion, it has been specifically flagged. If it appears in your formulations, passive monitoring is not enough.

Insufficient Data: This is the category that defines the current moment. Nineteen of the 25 ingredients reviewed — including Perfluorononyl Dimethicone and Trifluoroacetyl Tripeptide-2 — cannot be conclusively assessed because the toxicological evidence simply does not yet exist. That may sound like neutral ground. In practice, it is not. Regulators in multiple jurisdictions are treating data gaps as precautionary triggers, and that posture is hardening, not softening.

Legislation Is Already Moving

Waiting for a unified federal standard is not a viable compliance strategy. State-level action is already creating real, enforceable obligations.

Minnesota, Maine, New Mexico, Washington, and Connecticut have each enacted reporting and notification requirements for intentionally added PFAS in consumer products. These laws differ in scope and trigger points, but they share a common thread: manufacturers must know what is in their products, disclose it, and in some cases justify it.

More states are advancing similar legislation. Globally, parallel frameworks are tightening across major markets. The regulatory map is being redrawn — and it is being redrawn around intentional use specifically.

What This Demands from Manufacturers

The cumulative picture — FDA findings, state legislation, global regulatory momentum — points to one clear requirement: formulation accountability at a level most brands have not yet built.

That means moving beyond ingredient lists to a posture where every intentionally added PFAS is identified across the full product portfolio, every applicable reporting obligation is mapped by jurisdiction, documentation is structured to support regulatory scrutiny, and reformulation pathways are evaluated before external pressure forces the decision.

None of this is optional infrastructure. It is becoming the baseline expectation.

Act on the Signal, Not the Deadline

Regulatory signals in the cosmetics industry have a reliable pattern: early attention from agencies becomes guidance, guidance becomes requirements, requirements become enforcement. The FDA's findings on PFAS represent that early signal. The state laws already in effect confirm the direction.

Manufacturers who treat this moment as an opportunity to build robust PFAS compliance capability will be positioned ahead of the next wave of requirements. Those waiting for a specific deadline to force action will find themselves managing compliance reactively — at greater cost, with fewer options, and under more scrutiny.

Understanding the OSHA Hazard Communication Standard

If your organization works with chemicals, regulatory compliance begins not with paperwork — it begins with understanding the framework that governs how chemical hazards are identified, communicated, and managed in the workplace.

What is the Hazard Communication Standard?

The Hazard Communication Standard (HCS) is a federal regulation developed by the Occupational Safety and Health Administration (OSHA) that requires employers to ensure workers are informed about the chemical hazards they may encounter on the job. Commonly referred to as the "Right-to-Know" standard, HCS establishes the legal foundation for workplace chemical safety across the United States.

Why It Matters

The core objective of HCS is straightforward: chemical hazards must be clearly identified and effectively communicated to every worker who may be exposed to them. Done well, a robust hazard communication program prevents workplace injuries and illnesses, promotes the safe handling and storage of hazardous substances, and enables a faster, more effective emergency response when incidents occur.

Non-compliance carries serious consequences. When hazard communication breaks down, workers may fail to recognize chemical risks, emergency response can be delayed or misdirected, and organizations face regulatory penalties, audit findings, and operational disruption.

The Five Pillars of Compliance

To meet HCS requirements, employers must implement a comprehensive hazard communication program covering five core areas:

1. Hazard Classification Employers must systematically identify and classify the health and physical hazards associated with each chemical in their workplace. Classifications must be based on scientific data and evidence, and all classification decisions must be documented.

2. Container Labeling Every chemical container must bear a compliant label that includes the product identifier, an appropriate signal word (either "Danger" or "Warning"), hazard and precautionary statements, standardized pictograms, and supplier contact information.

3. Safety Data Sheets (SDS) A Safety Data Sheet must be maintained for every hazardous chemical on site. Each SDS follows a standardized 16-section format covering chemical properties, health hazards, safe handling procedures, required personal protective equipment (PPE), and emergency response measures. SDS documents must be readily accessible to employees at all times during their shifts.

4. Employee Training Workers must receive training that equips them to understand the chemical hazards present in their specific work environment, interpret labels and SDS documents accurately, apply safe handling practices, use appropriate PPE, and respond effectively in an emergency.

5. Written Hazard Communication Program Employers must maintain a written HazCom program that documents the organization's approach to chemical inventory management, labeling systems, SDS administration, and employee training procedures. This document is the backbone of an auditable compliance program.

What's Changing: HCS Updates Aligned with GHS

OSHA has issued significant updates to the HCS, aligning it more closely with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). These revisions introduce updated hazard classification criteria and revised requirements for labels and SDS content.

Compliance deadlines are phased:

May 19, 2026 — Updated requirements apply to substances

November 19, 2027 — Updated requirements apply to mixtures

Organizations should not treat these deadlines as distant. Reviewing and updating SDS documents, container labels, classification decisions, and training programs takes time — and the substances deadline is already upon us.

The Path Forward